SNPMiner Trials (Home Page)
Report for SNP rs2075606
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 An Open Label Phase II Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma
Platinum-based chemotherapy is now regarded a standard first-line treatment for patients with advanced urothelial carcinoma (UC). However, patients who failed to response or experienced progression after platinum-based chemotherapy have a grim prognosis and a standard salvage treatment is not available. UC is known to harbor multiple mutations. In the investigators' own high-throughput molecular profiling study, the most commonly observed mutations included TP53, FGFR3(fibroblast growth factor receptor 3 ) and HRAS. Since RAS signaling can be attenuated using selective farnesyl transferase (FTase) inhibitors, tipifarnib, a highly potent and selective inhibitor of FTase, was proposed to be an effective therapeutic approach in the treatment of UC.
NCT02535650 Urothelial Carcinoma Drug: tipifarnib MeSH:Carcinoma Carcinoma, Transitional Cell
HPO:Carcinoma
(missence non-synonymous HRAS mutation and/or STK11: rs2075606 (T>C))HRAS status may have been assessed either in primary tumor tissue, recurrent or metastatic disease. 5. Subject has consented to provide at least 10 unstained tumor slides for retrospective testing of HRAS gene tumor status.
Primary Outcomes
Measure: 6-month progression-free survival Time: Up to 6 months for each subjectSecondary Outcomes
Measure: Duration of response Time: Up to 12 months for each subjectMeasure: Overall survival Time: Until the date of death from any cause, whichever came first, assessed up to 1 year 6 months.
Description: Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0(Common Toxicity Criteria for Adverse Effects )
Measure: Safety and Tolerability Time: Up to 12 months for each subject